These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34848552)

  • 21. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-acute sequelae of SARS-CoV-2 infection (PASC): a protocol for a multidisciplinary prospective observational evaluation of a cohort of patients surviving hospitalisation in Sao Paulo, Brazil.
    Busatto GF; de Araújo AL; Duarte AJDS; Levin AS; Guedes BF; Kallas EG; Pinna FR; de Souza HP; da Silva KR; Sawamura MVY; Seelaender M; Imamura M; Garcia ML; Forlenza OV; Nitrini R; Damiano RF; Rocha VG; Batisttella LR; Carvalho CRR; ;
    BMJ Open; 2021 Jun; 11(6):e051706. PubMed ID: 34193506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal testing for severe acute respiratory syndrome coronavirus 2 in 2 Philadelphia hospitals: carrier prevalence and symptom development over 2 weeks.
    Bender WR; Hirshberg A; Coutifaris P; Acker AL; Srinivas SK
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100226. PubMed ID: 32954248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychological distress and health-related quality of life in patients after hospitalization during the COVID-19 pandemic: A single-center, observational study.
    Vlake JH; Wesselius S; van Genderen ME; van Bommel J; Boxma-de Klerk B; Wils EJ
    PLoS One; 2021; 16(8):e0255774. PubMed ID: 34379644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute Muscle Mass Loss Predicts Long-Term Fatigue, Myalgia, and Health Care Costs in COVID-19 Survivors.
    Gil S; de Oliveira Júnior GN; Sarti FM; Filho WJ; Longobardi I; Turri JAO; Shinjo SK; Ferriolli E; Avelino-Silva TJ; Busse AL; Gualano B; Roschel H
    J Am Med Dir Assoc; 2023 Jan; 24(1):10-16. PubMed ID: 36493804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
    Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
    Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study.
    García-Abellán J; Padilla S; Fernández-González M; García JA; Agulló V; Andreo M; Ruiz S; Galiana A; Gutiérrez F; Masiá M
    J Clin Immunol; 2021 Oct; 41(7):1490-1501. PubMed ID: 34273064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-Year Health Outcomes in Hospitalized COVID-19 Survivors in China.
    Yang X; Hou C; Shen Y; Zhang M; Zhang K; Wang F; Liu Y; Ma X; Cheng L; Kang J; Hu B; Wang M; Zeng L; Wang Y; He Y; Cao G; Jiang J; Jones P; Cao B; Li L
    JAMA Netw Open; 2022 Sep; 5(9):e2231790. PubMed ID: 36107425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
    García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
    Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge.
    Liang L; Yang B; Jiang N; Fu W; He X; Zhou Y; Ma WL; Wang X
    J Korean Med Sci; 2020 Dec; 35(47):e418. PubMed ID: 33289374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge.
    Bellan M; Soddu D; Balbo PE; Baricich A; Zeppegno P; Avanzi GC; Baldon G; Bartolomei G; Battaglia M; Battistini S; Binda V; Borg M; Cantaluppi V; Castello LM; Clivati E; Cisari C; Costanzo M; Croce A; Cuneo D; De Benedittis C; De Vecchi S; Feggi A; Gai M; Gambaro E; Gattoni E; Gramaglia C; Grisafi L; Guerriero C; Hayden E; Jona A; Invernizzi M; Lorenzini L; Loreti L; Martelli M; Marzullo P; Matino E; Panero A; Parachini E; Patrucco F; Patti G; Pirovano A; Prosperini P; Quaglino R; Rigamonti C; Sainaghi PP; Vecchi C; Zecca E; Pirisi M
    JAMA Netw Open; 2021 Jan; 4(1):e2036142. PubMed ID: 33502487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CovEMERALD: Assessing the feasibility and preliminary effectiveness of remotely delivered Eye Movement Desensitisation and Reprocessing following Covid-19 related critical illness: A structured summary of a study protocol for a randomised controlled trial.
    Bates A; Rushbrook S; Shapiro E; Grocott M; Cusack R
    Trials; 2020 Nov; 21(1):929. PubMed ID: 33203440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Symptoms Among Adults Tested for SARS-CoV-2 - United States, January 2020-April 2021.
    Wanga V; Chevinsky JR; Dimitrov LV; Gerdes ME; Whitfield GP; Bonacci RA; Nji MAM; Hernandez-Romieu AC; Rogers-Brown JS; McLeod T; Rushmore J; Lutfy C; Bushman D; Koumans E; Saydah S; Goodman AB; Coleman King SM; Jackson BR; Cope JR
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(36):1235-1241. PubMed ID: 34499626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-Discharge Symptoms among Hospitalized COVID-19 Patients in Nigeria: A Single-Center Study.
    Ogoina D; James HI; Ogoinja SZ
    Am J Trop Med Hyg; 2021 Jul; 105(3):731-736. PubMed ID: 34270448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Social Distance in COVID-19: Drawing the line between protective behavior and stigma manifestation.
    Economou M
    Psychiatriki; 2021 Sep; 32(3):183-186. PubMed ID: 34390552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
    Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
    Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.